A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Table 3 Best tumor response in HER2+ breast and gastric patients following treatment with MK-2206 and trastuzumab

Patient	Age (years)	Sex	Diagnosis	MK-2206 dose	Prior lines of therapy	Trastuzumab-free interval (days)	Reason for discontinuing prior trastuzumab	Time to progressive disease/withdrawal (days)	Best response
A	40 to 49	Female	Breast cancer	60 mg QOD	5	41	Progressive disease	167	SD (unconfirmed PR)
B	50 to 59	Female	Breast cancer	60 mg QOD	4	21	Progressive disease	164	SD
C	50 to 59	Male	Gastric cancer	200 mg QW	2	0	Trastuzumab not given	171	SD
D	50 to 59	Female	Breast cancer	60 mg QOD	8	48	Unknown	219	SD
E	40 to 49	Female	Breast cancer	135 mg QW	5	68	Completed therapy	105	SD
F	50 to 59	Female	Breast cancer	60 mg QOD	3	0	Progressive disease	388 (withdraw)^a	PR
7	50 to 59	Female	Breast cancer	135 mg QW	5	28	Progressive disease	106 (withdraw)	CR

CR, complete response; HER2, human epidermal growth factor receptor 2; PR, partial response; QOD, every other day; QW, every week; SD, stable disease. ^aPatient was on trial for 173 days and then continued receiving treatment after database lock for a total of 388 days before withdrawing due to skin rash.

ISSN: 1465-542X